A prospective study to evaluate the role of complexed prostate specific antigen and free/total prostate specific antigen ratio for the diagnosis of prostate cancer

I. D. Mitchell, Bernard Lewis Croal, N. P. Cohen, A. Dickie, I. Ross

    Research output: Contribution to journalArticle

    49 Citations (Scopus)

    Abstract

    Purpose: Patients are increasingly undergoing prostatic biopsy to identify localized prostate cancer. The decision to perform a biopsy is often made on the basis of total prostate specific antigen (PSA). However, this value lacks adequate specificity for this task. We evaluate the role that a number of these tests, including the Bayer complexed PSA (Bayer Diagnostics, Tarrytown, New York) and free/total PSA ratio, may have in our clinical practice.

    Materials and Methods: A total of 160 consecutive patients attending a prostate assessment clinic were enrolled during an 18-month period in our study. All patients had a previously recorded total PSA (range 2.6 to 20.0 ng./ml.). Before transrectal ultrasound biopsy of the prostate gland, a blood sample was taken with patient consent. The findings on ultrasound were then recorded, including prostate volume. Serum samples were immediately sent for subsequent storage and analysis.

    Results: Of the patients enrolled 109 had benign histology while 51 had prostatic carcinoma. The 2 patient groups were well matched for age. In our series patients with prostate cancer had significantly smaller prostates and higher mean total PSA. At a high sensitivity, such as 95%, it appeared that Bayer complexed PSA performed better than the other tests and ratios, with an estimated specificity of 24.8% compared with 17.4% for Bayer total PSA and 15.6% for Abbott free/total PSA (Abbott Laboratories, Abbott Park, Illinois). Receiver operator characteristics curves were drawn, and when the areas under them were calculated, we demonstrated that the area under the curve for Bayer complexed PSA (0.706) was between the values for total PSA (0.671) and free/total PSA ratio (0.731). However, the only statistically significant improvement in performance was in Payer complexed PSA over the total PSA assays.

    Conclusions: Our study revealed that the overall diagnostic performance of Bayer complexed PSA appears to be better than the other PSA tests and ratios studied. The use of Bayer complexed PSA may lead to a reduction in the number of men undergoing unnecessary prostatic biopsy.

    Original languageEnglish
    Pages (from-to)1549-1553
    Number of pages4
    JournalJournal of Urology
    Volume165
    Issue number5
    DOIs
    Publication statusPublished - 2001

    Keywords

    • prostate
    • prostate-specific antigen
    • prostatic neoplasms
    • PSA
    • SERUM
    • HYPERPLASIA
    • MEN
    • DIFFERENTIATION
    • DISEASE

    Cite this

    A prospective study to evaluate the role of complexed prostate specific antigen and free/total prostate specific antigen ratio for the diagnosis of prostate cancer. / Mitchell, I. D.; Croal, Bernard Lewis; Cohen, N. P.; Dickie, A.; Ross, I.

    In: Journal of Urology, Vol. 165, No. 5, 2001, p. 1549-1553.

    Research output: Contribution to journalArticle

    Mitchell, I. D. ; Croal, Bernard Lewis ; Cohen, N. P. ; Dickie, A. ; Ross, I. / A prospective study to evaluate the role of complexed prostate specific antigen and free/total prostate specific antigen ratio for the diagnosis of prostate cancer. In: Journal of Urology. 2001 ; Vol. 165, No. 5. pp. 1549-1553.
    @article{f6f4a205e550413caa76021082572093,
    title = "A prospective study to evaluate the role of complexed prostate specific antigen and free/total prostate specific antigen ratio for the diagnosis of prostate cancer",
    abstract = "Purpose: Patients are increasingly undergoing prostatic biopsy to identify localized prostate cancer. The decision to perform a biopsy is often made on the basis of total prostate specific antigen (PSA). However, this value lacks adequate specificity for this task. We evaluate the role that a number of these tests, including the Bayer complexed PSA (Bayer Diagnostics, Tarrytown, New York) and free/total PSA ratio, may have in our clinical practice.Materials and Methods: A total of 160 consecutive patients attending a prostate assessment clinic were enrolled during an 18-month period in our study. All patients had a previously recorded total PSA (range 2.6 to 20.0 ng./ml.). Before transrectal ultrasound biopsy of the prostate gland, a blood sample was taken with patient consent. The findings on ultrasound were then recorded, including prostate volume. Serum samples were immediately sent for subsequent storage and analysis.Results: Of the patients enrolled 109 had benign histology while 51 had prostatic carcinoma. The 2 patient groups were well matched for age. In our series patients with prostate cancer had significantly smaller prostates and higher mean total PSA. At a high sensitivity, such as 95{\%}, it appeared that Bayer complexed PSA performed better than the other tests and ratios, with an estimated specificity of 24.8{\%} compared with 17.4{\%} for Bayer total PSA and 15.6{\%} for Abbott free/total PSA (Abbott Laboratories, Abbott Park, Illinois). Receiver operator characteristics curves were drawn, and when the areas under them were calculated, we demonstrated that the area under the curve for Bayer complexed PSA (0.706) was between the values for total PSA (0.671) and free/total PSA ratio (0.731). However, the only statistically significant improvement in performance was in Payer complexed PSA over the total PSA assays.Conclusions: Our study revealed that the overall diagnostic performance of Bayer complexed PSA appears to be better than the other PSA tests and ratios studied. The use of Bayer complexed PSA may lead to a reduction in the number of men undergoing unnecessary prostatic biopsy.",
    keywords = "prostate, prostate-specific antigen, prostatic neoplasms, PSA, SERUM, HYPERPLASIA, MEN, DIFFERENTIATION, DISEASE",
    author = "Mitchell, {I. D.} and Croal, {Bernard Lewis} and Cohen, {N. P.} and A. Dickie and I. Ross",
    year = "2001",
    doi = "10.1016/S0022-5347(05)66346-X",
    language = "English",
    volume = "165",
    pages = "1549--1553",
    journal = "Journal of Urology",
    issn = "0022-5347",
    publisher = "Elsevier Inc.",
    number = "5",

    }

    TY - JOUR

    T1 - A prospective study to evaluate the role of complexed prostate specific antigen and free/total prostate specific antigen ratio for the diagnosis of prostate cancer

    AU - Mitchell, I. D.

    AU - Croal, Bernard Lewis

    AU - Cohen, N. P.

    AU - Dickie, A.

    AU - Ross, I.

    PY - 2001

    Y1 - 2001

    N2 - Purpose: Patients are increasingly undergoing prostatic biopsy to identify localized prostate cancer. The decision to perform a biopsy is often made on the basis of total prostate specific antigen (PSA). However, this value lacks adequate specificity for this task. We evaluate the role that a number of these tests, including the Bayer complexed PSA (Bayer Diagnostics, Tarrytown, New York) and free/total PSA ratio, may have in our clinical practice.Materials and Methods: A total of 160 consecutive patients attending a prostate assessment clinic were enrolled during an 18-month period in our study. All patients had a previously recorded total PSA (range 2.6 to 20.0 ng./ml.). Before transrectal ultrasound biopsy of the prostate gland, a blood sample was taken with patient consent. The findings on ultrasound were then recorded, including prostate volume. Serum samples were immediately sent for subsequent storage and analysis.Results: Of the patients enrolled 109 had benign histology while 51 had prostatic carcinoma. The 2 patient groups were well matched for age. In our series patients with prostate cancer had significantly smaller prostates and higher mean total PSA. At a high sensitivity, such as 95%, it appeared that Bayer complexed PSA performed better than the other tests and ratios, with an estimated specificity of 24.8% compared with 17.4% for Bayer total PSA and 15.6% for Abbott free/total PSA (Abbott Laboratories, Abbott Park, Illinois). Receiver operator characteristics curves were drawn, and when the areas under them were calculated, we demonstrated that the area under the curve for Bayer complexed PSA (0.706) was between the values for total PSA (0.671) and free/total PSA ratio (0.731). However, the only statistically significant improvement in performance was in Payer complexed PSA over the total PSA assays.Conclusions: Our study revealed that the overall diagnostic performance of Bayer complexed PSA appears to be better than the other PSA tests and ratios studied. The use of Bayer complexed PSA may lead to a reduction in the number of men undergoing unnecessary prostatic biopsy.

    AB - Purpose: Patients are increasingly undergoing prostatic biopsy to identify localized prostate cancer. The decision to perform a biopsy is often made on the basis of total prostate specific antigen (PSA). However, this value lacks adequate specificity for this task. We evaluate the role that a number of these tests, including the Bayer complexed PSA (Bayer Diagnostics, Tarrytown, New York) and free/total PSA ratio, may have in our clinical practice.Materials and Methods: A total of 160 consecutive patients attending a prostate assessment clinic were enrolled during an 18-month period in our study. All patients had a previously recorded total PSA (range 2.6 to 20.0 ng./ml.). Before transrectal ultrasound biopsy of the prostate gland, a blood sample was taken with patient consent. The findings on ultrasound were then recorded, including prostate volume. Serum samples were immediately sent for subsequent storage and analysis.Results: Of the patients enrolled 109 had benign histology while 51 had prostatic carcinoma. The 2 patient groups were well matched for age. In our series patients with prostate cancer had significantly smaller prostates and higher mean total PSA. At a high sensitivity, such as 95%, it appeared that Bayer complexed PSA performed better than the other tests and ratios, with an estimated specificity of 24.8% compared with 17.4% for Bayer total PSA and 15.6% for Abbott free/total PSA (Abbott Laboratories, Abbott Park, Illinois). Receiver operator characteristics curves were drawn, and when the areas under them were calculated, we demonstrated that the area under the curve for Bayer complexed PSA (0.706) was between the values for total PSA (0.671) and free/total PSA ratio (0.731). However, the only statistically significant improvement in performance was in Payer complexed PSA over the total PSA assays.Conclusions: Our study revealed that the overall diagnostic performance of Bayer complexed PSA appears to be better than the other PSA tests and ratios studied. The use of Bayer complexed PSA may lead to a reduction in the number of men undergoing unnecessary prostatic biopsy.

    KW - prostate

    KW - prostate-specific antigen

    KW - prostatic neoplasms

    KW - PSA

    KW - SERUM

    KW - HYPERPLASIA

    KW - MEN

    KW - DIFFERENTIATION

    KW - DISEASE

    U2 - 10.1016/S0022-5347(05)66346-X

    DO - 10.1016/S0022-5347(05)66346-X

    M3 - Article

    VL - 165

    SP - 1549

    EP - 1553

    JO - Journal of Urology

    JF - Journal of Urology

    SN - 0022-5347

    IS - 5

    ER -